RGEN promotion. Sadness..

Today the company's shares Repligen Corporation RGEN opened with a gap against the trend by more than 40 Percent. The reason for the fall – FDA, who had to decide if RG1068 should be approved, canceled the meeting with the company's consultants, scheduled for May.Experimental a drug is a synthetic версию человеческого secretin, which improves identifying violations pancreas in combination with MRT in patients with pancreatitis in the final Phase research.